American Bio Medica (ABMC) stock price, revenue, and financials

American Bio Medica market cap is $35.1 m, and annual revenue was $3.66 m in FY 2019

$35.1 M

ABMC Mkt cap, 09-Jul-2020

$3.7 M

American Bio Medica Revenue FY, 2019
American Bio Medica Gross profit (FY, 2019)1.2 M
American Bio Medica Gross profit margin (FY, 2019), %32.4%
American Bio Medica Net income (FY, 2019)-681 K
American Bio Medica EBIT (FY, 2019)-593 K
American Bio Medica Cash, 31-Dec-20194 K
American Bio Medica EV36.6 M

American Bio Medica Revenue

American Bio Medica revenue was $3.66 m in FY, 2019

Embed Graph

American Bio Medica Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

2.5m2.4m2.3m2.5m2.3m2.1m2.4m2.3m2.0m1.8m1.8m1.5m1.8m1.6m1.5m1.5m1.4m1.3m1.3m1.4m1.0m1.1m878.0k923.0k958.0k895.0k

Cost of goods sold

1.3m1.4m1.3m1.4m1.4m1.3m1.4m1.4m1.2m1.0m1.0m802.0k919.0k823.0k840.0k796.0k806.0k751.0k741.0k788.0k669.0k632.0k514.0k617.0k652.0k536.0k

Gross profit

1.2m966.0k962.0k1.0m891.0k786.0k969.0k906.0k877.0k791.0k723.0k700.0k849.0k767.0k630.0k709.0k611.0k565.0k565.0k566.0k372.0k437.0k364.0k306.0k306.0k359.0k

Gross profit Margin, %

46%41%42%42%39%37%41%40%43%44%41%47%48%48%43%47%43%43%43%42%36%41%41%33%32%40%

Sales and marketing expense

445.0k417.0k521.0k529.0k453.0k475.0k491.0k412.0k292.0k267.0k280.0k299.0k309.0k291.0k270.0k282.0k275.0k196.0k176.0k159.0k161.0k148.0k125.0k113.0k107.0k131.0k

R&D expense

57.0k61.0k52.0k55.0k54.0k63.0k115.0k315.0k46.0k45.0k92.0k29.0k51.0k45.0k54.0k55.0k28.0k46.0k22.0k26.0k25.0k19.0k20.0k19.0k20.0k23.0k

General and administrative expense

474.0k462.0k558.0k488.0k613.0k610.0k574.0k465.0k477.0k456.0k475.0k425.0k520.0k388.0k397.0k358.0k368.0k390.0k388.0k376.0k392.0k344.0k351.0k348.0k334.0k286.0k

Operating expense total

976.0k940.0k1.1m1.1m1.1m1.1m1.2m1.2m815.0k768.0k847.0k753.0k880.0k724.0k721.0k695.0k671.0k632.0k586.0k561.0k578.0k511.0k496.0k480.0k461.0k440.0k

EBIT

175.0k26.0k(169.0k)(30.0k)(229.0k)(362.0k)(211.0k)(286.0k)62.0k23.0k(124.0k)(53.0k)(31.0k)43.0k(91.0k)14.0k(60.0k)(67.0k)(21.0k)5.0k(206.0k)(74.0k)(132.0k)(174.0k)(155.0k)(81.0k)

EBIT margin, %

7%1%(7%)(1%)(10%)(17%)(9%)(13%)3%1%(7%)(4%)(2%)3%(6%)1%(4%)(5%)(2%)0%(20%)(7%)(15%)(19%)(16%)(9%)

Interest expense

50.0k49.0k46.0k45.0k38.0k63.0k82.0k70.0k63.0k15.0k45.0k

Interest income

4.0k1.0k3.0k2.0k1.0k1.0k1.0k150.0k6.0k44.0k20.0k14.0k10.0k4.0k1.0k1.0k

Pre tax profit

124.0k(23.0k)(211.0k)(74.0k)(264.0k)(423.0k)(293.0k)(216.0k)10.0k(41.0k)(211.0k)(45.0k)(83.0k)(2.0k)2.0k(44.0k)(87.0k)(132.0k)(70.0k)(51.0k)(267.0k)(145.0k)(202.0k)(240.0k)(54.0k)(144.0k)

Income tax expense

1.0k5.0k(5.0k)3.0k1.0k1.0k(3.0k)1.0k1.0k1.0k1.0k(2.0k)2.0k2.0k

Net Income

123.0k(28.0k)(206.0k)(77.0k)(264.0k)(424.0k)(294.0k)(213.0k)9.0k(41.0k)(211.0k)(45.0k)(83.0k)(2.0k)1.0k(44.0k)(88.0k)(132.0k)(71.0k)(49.0k)(267.0k)(147.0k)(202.0k)(240.0k)(56.0k)(144.0k)

American Bio Medica Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

22.0k22.0k6.0k15.0k1.0k55.0k63.0k521.0k447.0k433.0k487.0k433.0k224.0k97.0k178.0k221.0k136.0k138.0k150.0k92.0k76.0k59.0k54.0k99.0k15.0k

Accounts Receivable

1.1m1.1m940.0k1.2m1.2m907.0k1.1m952.0k909.0k742.0k782.0k648.0k859.0k802.0k789.0k720.0k721.0k611.0k482.0k521.0k421.0k512.0k546.0k392.0k393.0k492.0k

Prepaid Expenses

156.0k149.0k96.0k68.0k83.0k159.0k103.0k63.0k124.0k95.0k168.0k103.0k96.0k80.0k90.0k63.0k61.0k63.0k88.0k49.0k61.0k33.0k71.0k48.0k1.0k24.0k

Inventories

3.2m3.2m3.3m3.4m3.1m2.5m2.5m2.2m2.0m1.9m1.9m1.8m1.8m1.8m1.6m1.6m1.6m1.5m1.5m1.5m1.4m1.3m1.3m973.0k825.0k890.0k

Current Assets

4.5m4.5m4.4m4.6m4.4m3.5m3.7m3.3m3.6m3.3m3.3m3.1m3.2m3.0m2.6m2.6m2.6m2.3m2.2m2.2m2.0m1.9m1.9m1.5m1.3m1.4m

PP&E

1.3m1.3m1.3m1.3m1.2m1.2m1.2m1.1m1.1m1.0m976.0k957.0k942.0k923.0k887.0k866.0k844.0k805.0k823.0k810.0k774.0k754.0k736.0k699.0k681.0k663.0k

Total Assets

5.9m5.9m5.7m5.9m5.7m5.2m5.3m4.5m4.7m4.4m4.3m4.3m4.4m4.2m3.6m3.6m3.5m3.3m3.1m3.1m2.9m2.8m2.8m2.3m2.2m2.2m

Accounts Payable

600.0k684.0k877.0k1.4m1.0m698.0k648.0k762.0k633.0k462.0k510.0k423.0k508.0k429.0k470.0k376.0k305.0k304.0k278.0k306.0k430.0k349.0k459.0k521.0k555.0k606.0k

Short-term debt

119.0k879.0k1.5m1.4m1.4m1.3m1.3m1.3m1.1m886.0k855.0k977.0k1.1m1.0m696.0k768.0k811.0k825.0k681.0k667.0k729.0k833.0k832.0k1.5m1.4m1.5m

Current Liabilities

1.8m2.6m3.3m3.6m3.5m3.6m4.0m3.5m3.1m2.6m2.7m1.9m2.2m1.9m1.7m1.6m1.6m1.7m1.5m1.5m1.8m1.8m2.0m2.7m2.6m2.8m

Long-term debt

1.4m639.0k553.0k12.0k100.0k257.0k247.0k956.0k923.0k934.0k683.0k706.0k730.0k701.0k725.0k748.0k704.0k733.0k761.0k12.0k1.0k

Total Debt

1.5m1.5m1.5m1.4m1.4m1.9m1.3m1.4m1.1m1.1m247.0k1.9m998.0k1.0m1.4m1.5m1.5m1.5m1.4m667.0k1.4m1.6m1.6m1.4m378.0k431.0k

Total Liabilities

3.5m3.5m3.5m3.8m3.8m3.9m4.3m3.7m3.4m3.0m3.1m3.0m3.3m3.1m2.5m2.5m2.4m2.4m2.2m2.3m2.5m2.5m2.7m2.7m2.6m2.8m

Common Stock

217.0k217.0k217.0k217.0k217.0k222.0k222.0k222.0k232.0k232.0k236.0k260.0k260.0k260.0k272.0k273.0k285.0k288.0k293.0k293.0k299.0k300.0k302.0k325.0k325.0k325.0k

Preferred Stock

Additional Paid-in Capital

19.4m19.4m19.4m19.4m19.5m19.8m19.8m19.9m20.3m20.3m20.3m20.6m20.6m20.6m20.8m20.8m21.0m21.0m21.1m21.1m21.2m21.2m21.2m21.4m21.4m21.4m

Retained Earnings

(17.2m)(17.2m)(17.4m)(17.5m)(17.8m)(18.8m)(19.1m)(19.3m)(19.1m)(19.2m)(19.4m)(19.7m)(19.7m)(19.8m)(20.0m)(20.0m)(20.1m)(20.4m)(20.5m)(20.6m)(21.1m)(21.3m)(21.5m)(22.1m)(22.2m)(22.3m)

Total Equity

2.4m2.4m2.2m2.1m1.9m1.3m993.0k796.0k1.4m1.4m1.2m1.2m1.2m1.2m1.1m1.1m1.2m905.0k895.0k856.0k378.0k238.0k72.0k(367.0k)(419.0k)(563.0k)

Debt to Equity Ratio

0.6 x0.6 x0.7 x0.7 x0.7 x1.5 x1.3 x1.7 x0.8 x0.8 x0.2 x1.6 x0.9 x0.9 x1.2 x1.3 x1.3 x1.7 x1.6 x0.8 x3.8 x6.6 x22.1 x-3.9 x-0.9 x-0.8 x

Debt to Assets Ratio

0.3 x0.3 x0.3 x0.2 x0.3 x0.4 x0.3 x0.3 x0.2 x0.3 x0.1 x0.5 x0.2 x0.2 x0.4 x0.4 x0.4 x0.5 x0.4 x0.2 x0.5 x0.6 x0.6 x0.6 x0.2 x0.2 x

Financial Leverage

2.5 x2.5 x2.6 x2.8 x3 x4.1 x5.3 x5.7 x3.4 x3.3 x3.6 x3.5 x3.8 x3.6 x3.2 x3.3 x3 x3.6 x3.5 x3.7 x7.6 x11.7 x39 x-6.3 x-5.2 x-4 x

American Bio Medica Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(301.0k)(330.0k)(206.0k)(283.0k)(546.0k)(424.0k)(718.0k)(933.0k)9.0k(32.0k)(252.0k)(45.0k)(128.0k)(130.0k)1.0k(43.0k)(130.0k)(132.0k)(203.0k)(252.0k)(267.0k)(413.0k)(615.0k)(240.0k)(296.0k)(440.0k)

Depreciation and Amortization

137.0k208.0k30.0k61.0k91.0k29.0k59.0k87.0k28.0k58.0k85.0k25.0k45.0k70.0k23.0k46.0k69.0k22.0k43.0k64.0k20.0k42.0k61.0k20.0k42.0k61.0k

Accounts Receivable

(322.0k)(381.0k)(57.0k)(261.0k)(344.0k)(96.0k)(243.0k)(141.0k)(28.0k)145.0k105.0k168.0k(49.0k)13.0k(117.0k)(48.0k)(49.0k)(55.0k)74.0k32.0k(72.0k)(168.0k)(202.0k)60.0k59.0k(38.0k)

Inventories

389.0k434.0k(98.0k)(199.0k)92.0k50.0k(7.0k)258.0k105.0k127.0k189.0k(111.0k)(144.0k)(189.0k)104.0k93.0k127.0k58.0k113.0k116.0k64.0k171.0k209.0k25.0k153.0k66.0k

Accounts Payable

168.0k252.0k244.0k751.0k394.0k(318.0k)(368.0k)(253.0k)36.0k(135.0k)(87.0k)13.0k98.0k19.0k98.0k3.0k(38.0k)(26.0k)2.0k56.0k(25.0k)85.0k162.0k196.0k247.0k

Cash From Operating Activities

31.0k191.0k(155.0k)38.0k(125.0k)(743.0k)(1.0m)(505.0k)187.0k213.0k204.0k177.0k91.0k105.0k172.0k185.0k185.0k(47.0k)116.0k158.0k(56.0k)(166.0k)(171.0k)52.0k144.0k(5.0k)

Purchases of PP&E

(61.0k)(141.0k)(1.0k)(8.0k)(12.0k)(11.0k)(57.0k)(30.0k)(7.0k)(21.0k)(4.0k)(10.0k)(38.0k)(44.0k)

Cash From Investing Activities

(61.0k)(141.0k)(21.0k)(31.0k)(35.0k)(11.0k)(57.0k)(33.0k)(1.0k)(12.0k)(22.0k)(2.0k)(7.0k)(14.0k)(3.0k)(6.0k)(6.0k)(9.0k)(51.0k)(64.0k)(6.0k)(13.0k)(21.0k)

Short-term Borrowings

(87.0k)(27.0k)(121.0k)20.0k(168.0k)(3.2m)(5.9m)(7.9m)(2.1m)(3.7m)(5.3m)(1.4m)(3.5m)(5.2m)(1.7m)(3.2m)(4.6m)(1.3m)(2.9m)(4.8m)(1.0m)(2.1m)(3.0m)(1.0m)(2.0m)(2.9m)

Long-term Borrowings

(2.4m)(4.6m)(130.0k)(72.0k)(78.0k)(81.0k)(85.0k)

Cash From Financing Activities

15.0k(65.0k)89.0k(85.0k)67.0k666.0k1.0m512.0k(311.0k)(400.0k)(395.0k)(40.0k)(3.0k)(219.0k)(231.0k)(159.0k)(116.0k)36.0k(83.0k)(100.0k)118.0k219.0k215.0k(111.0k)(158.0k)(93.0k)

Net Change in Cash

(15.0k)(15.0k)(87.0k)(78.0k)(93.0k)(88.0k)(34.0k)(26.0k)(125.0k)(199.0k)(213.0k)135.0k81.0k(128.0k)(61.0k)20.0k63.0k(20.0k)(18.0k)(6.0k)56.0k40.0k23.0k(59.0k)(14.0k)(98.0k)

Interest Paid

101.0k170.0k65.0k93.0k152.0k48.0k120.0k198.0k46.0k126.0k186.0k31.0k131.0k176.0k39.0k79.0k119.0k40.0k71.0k110.0k36.0k76.0k118.0k39.0k79.0k117.0k

Income Taxes Paid

1.0k2.0k1.0k(1.0k)2.0k2.0k2.0k2.0k

American Bio Medica Ratios

USDQ2, 2011

Debt/Equity

0.6 x

Debt/Assets

0.3 x

Financial Leverage

2.5 x
0